Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.
Science 37 Holdings Inc. (SNCE) leads the transformation of clinical research through its decentralized trial platform combining telemedicine and networked trial solutions. This news hub provides investors and healthcare professionals with essential updates on the company's operational developments and industry leadership.
Access real-time announcements about clinical trial milestones, regulatory compliance achievements, and strategic partnerships. Our curated collection features earnings reports, technology innovations like the Metasite™ platform, and patient enrollment breakthroughs that demonstrate Science 37's impact on modern clinical research.
Key updates include progress in decentralized trial models, collaborations with medical institutions, and advancements in virtual patient recruitment. Bookmark this page to stay informed about how SNCE continues to redefine clinical trial accessibility while maintaining rigorous quality standards across all operations.
Science 37 Holdings, Inc. (Nasdaq: SNCE) has appointed Irena Lambridis as its new Global Head of Quality Assurance & Compliance, aiming to enhance the company's quality oversight as it expands globally across its new Centers of Excellence in India, Pakistan, and Slovakia.
Irena brings nearly 20 years of clinical research quality assurance experience, previously holding leadership roles at KCR and Novella Clinical, now part of IQVIA Biotech. Her expertise will help ensure adherence to quality standards and regulatory compliance.
This appointment aligns with Science 37's mission to lead in quality within the decentralized clinical trials (DCT) industry and supports its goal of accelerating patient access to clinical research.
Science 37 Holdings (Nasdaq: SNCE) announced a business update conference call scheduled for April 12, 2023, at 8:30 a.m. Eastern Time. The call will assess recent business developments and can be joined via toll-free or international numbers, as well as through a dedicated link. The live webcast will be accessible on the company’s investor relations webpage, with a replay available for 90 days post-event.
Science 37 is recognized for its innovative Metasite™ model, which enhances clinical research by allowing universal patient access through technology, mobile nursing, and remote coordination. This approach facilitates patient participation from various locations, broadening patient diversity and ensuring high-quality data collection. For more information, visit their website.
Science 37 Holdings, Inc. (Nasdaq: SNCE) announced the launch of three global Centers of Excellence (COEs) in India, Pakistan, and Slovakia to enhance its Metasite offering. This initiative aims to improve operational efficiency and accelerate profitability. The COEs will focus on technology platform development and employ skilled talent in data management. As of end-2022, the company employed 85 individuals in these regions, expecting to expand this number to nearly 200 by year-end 2023, while simultaneously eliminating approximately 140 positions in the U.S. and Europe.
In a strong first quarter, preliminary results indicated gross bookings exceeding $23 million and revenue surpassing $13.5 million, ahead of expectations. However, the company anticipates a $12 million adjustment to gross bookings due to prior halted projects. The preliminary financial results are subject to final adjustments.
Science 37 Holdings (Nasdaq: SNCE) announced on April 10, 2023, the granting of inducement equity awards under its 2022 Employment Inducement Incentive Award Plan. This plan, approved by the Board of Directors in November 2022, aims to attract non-executive employees. Three new employees received options to purchase a total of 110,800 shares of common stock at an exercise price of $0.29 per share, the closing price on the grant date. The options have a ten-year term and a four-year vesting schedule, with the first 25% vesting on the anniversary of the grant date. Science 37 focuses on improving clinical research accessibility through its Metasite™, leveraging proprietary technology for enhanced patient participation.
On March 10, 2023, Science 37 Holdings, Inc. (NASDAQ: SNCE) announced the granting of inducement equity awards under its 2022 Employment Inducement Incentive Award Plan. This was approved by the company's Board of Directors and Compensation Committee. A total of 86,300 stock options were granted to 13 new employees at an exercise price of $0.24 per share, equal to the closing price on the grant date. The options have a 10-year term and a four-year vesting schedule. Science 37 aims to enhance clinical research accessibility through its Metasite™ model, allowing patients to participate conveniently from various locations.
Science 37 Holdings reported its Q4 and full-year results for 2022, revealing a 22% decline in quarterly revenue to $15.9 million. Net bookings for the quarter fell 57% year-over-year to $18.6 million. Gross profit decreased to $3.6 million, with a gross margin of 22.9%. The net loss for Q4 was $66.5 million, equating to a loss per share of $0.57. For the year, revenue totaled $70.1 million, an 18% increase, but net bookings dropped 52%.
Looking ahead, the company forecasts 2023 revenue between $55.0 million and $60.0 million with adjusted EBITDA guidance of a loss between $(50.0) million and $(48.0) million.
Science 37 Holdings, Inc. (Nasdaq: SNCE) will present at the Cowen 43rd Annual Health Care Conference in Boston on March 8, 2023, at 9:10 a.m. ET. The presentation will be accessible live and archived on the company's investor relations website.
Science 37 is a leader in accelerating clinical research through its unique Metasite™, allowing universal access for patients. This innovative model expands patient recruitment capabilities while ensuring diversity, enabling participation from home or local providers. The company is committed to delivering high-quality data using advanced technology and in-house expertise.
Science 37 Holdings (Nasdaq: SNCE) will announce its fourth quarter 2022 financial results before the market opens on March 6, 2023. The management team will hold a conference call at 8:30 a.m. ET on the same day to discuss the results, accessible via phone or through an online link for immediate connection. Science 37 focuses on accelerating clinical research by providing universal trial access, employing a proprietary technology platform to enhance patient diversity and participation flexibility. The firm operates as a single Metasite™ to facilitate research participation, allowing remote access or traditional site involvement as needed.
Science 37 Holdings, Inc. (Nasdaq: SNCE) has granted inducement equity awards under its 2022 Employment Inducement Incentive Award Plan. The Board approved this plan in November 2022. On February 10, 2023, options to purchase 150,700 shares at an exercise price of $0.42 were awarded to 16 new non-executive employees, representing the closing price on the grant date. The options have a 10-year term with a four-year vesting schedule. This move is aimed at attracting talent to aid in the company's mission to enhance clinical research access.
Science 37 Holdings (Nasdaq: SNCE) has announced its acquisition of the life sciences platform from Vault Health, aimed at enhancing clinical trial workflow and data interoperability. This acquisition is expected to accelerate the development of advanced scheduling and tracking features, streamlining decentralized clinical trials by reducing manual efforts and driving operational efficiencies. CEO David Coman noted that the asset will integrate seamlessly into existing operations, impacting efficiency by the second half of 2023. The deal is projected to be cash flow neutral within the calendar year and will avoid planned spending costs for Science 37.
